Clinical Trial Detail

NCT ID NCT03401788
Title A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Peloton Therapeutics, Inc.
Indications

von Hippel-Lindau disease

renal cell carcinoma

Therapies

PT 2977

Age Groups: senior adult

Additional content available in CKB BOOST